Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential versus delayed AC followed by CMF with tamoxifen or toremifene in node-positive post/perimenopausal breast cancer
ACTRN12607000034437Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Jul 1993
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, epirubicin, cyclophosphamide, methotrexate, fluorouracil and 2 more in breast cancer (4 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Disease-free survival. Started Jul 1993; status: completed.
02
Drugs
doxorubicinepirubicincyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000034437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000034437.